BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sato-Espinoza K, Chotiprasidhi P, Huaman MR, Díaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2024; 16(3): 452-464 [PMID: 38577539 DOI: 10.4254/wjh.v16.i3.452]
URL: https://www.wjgnet.com/1007-9327/full/v16/i3/452.htm
Number Citing Articles
1
E. E. Zabotina, Yu. A. Khabarova, N. Yu. Stukova. Metabolic dysfunction associated steatotic liver disease in lean patients. Diagnostic and treatment challengesExperimental and Clinical Gastroenterology 2025; (9): 96 doi: 10.31146/1682-8658-ecg-229-9-96-109
2
Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou. Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discoveryExpert Opinion on Drug Discovery 2025; : 1 doi: 10.1080/17460441.2025.2579124
3
Priyankar Dey. The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different?Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1693123
4
Jan Best, Julia Kälsch, Marcin Krawczyk, Paul Manka, Ali Canbay, Hartmut Schmidt, Leonie Jochheim. Metabolische Dysfunktion-assoziierte steatotische Lebererkrankung und hepatozelluläres KarzinomDie Gastroenterologie 2025; 20(2): 123 doi: 10.1007/s11377-025-00878-z
5
Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam. Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancementNaunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(10): 13647 doi: 10.1007/s00210-025-04257-x
6
Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka. Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patientsPolish Annals of Medicine 2025; : 1 doi: 10.29089/paom/203734
7
Lampros Chrysavgis, Evangelos Cholongitas. From NAFLD to MASLD: what does it mean?Expert Review of Gastroenterology & Hepatology 2024; 18(6): 217 doi: 10.1080/17474124.2024.2374472
8
Fabio Novielli, Carlo De Matteis, Antonio Moschetta, Lucilla Crudele. Non-invasive assessment of liver fibrosis in MASLD: the need of sex-adjusted scoresExpert Review of Gastroenterology & Hepatology 2025; 19(10): 1081 doi: 10.1080/17474124.2025.2557243
9
Su-Qun Li, Jin-Hua Wu, Ying Zhou, Chen-Xi Wang, Li Xie, Si-Ying Liu, Yu-Zhi Su, Wei He, Huan Chen, Wei-Wei Zhong, Yi-Huai He. Hepatocyte nuclear factors dynamically regulate triglyceride metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: Mechanisms and implicationsWorld Journal of Hepatology 2025; 17(10): 109898 doi: 10.4254/wjh.v17.i10.109898
10
Karina Sato-Espinoza, Perapa Chotiprasidhi, Estefanía Liza, Zuly Placido-Damian, Javier Diaz-Ferrer. Evolution of liver transplantation in the metabolic dysfunction-associated steatotic liver disease era: Tracking impact through timeWorld Journal of Transplantation 2024; 14(4): 98718 doi: 10.5500/wjt.v14.i4.98718